These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Endocrinologic features and the effect of dantrolene sodium in a subject with recurrent muscle spasms (author's transl)]. Takeuchi A; Kobayashi I; Nagasawa T; Nakazawa T; Inui S Nihon Naika Gakkai Zasshi; 1976 Aug; 65(8):778-84. PubMed ID: 988100 [No Abstract] [Full Text] [Related]
43. Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease. Weiser R; Terenty T; Hudgson P; Weightman D Practitioner; 1978 Jul; 221(1321):123-7. PubMed ID: 366589 [No Abstract] [Full Text] [Related]
44. A form of chorea that responds to dantrolene sodium. Feit H Neurology; 1979 Dec; 29(12):1631-2. PubMed ID: 159420 [No Abstract] [Full Text] [Related]
45. Letter: Hallucinations associated with dantrolene sodium therapy. Andrews LG; Muzumdar AS; Pinkerton AC Can Med Assoc J; 1975 Jan; 112(2):148. PubMed ID: 1111870 [No Abstract] [Full Text] [Related]
46. Dantrolene sodium (Dantrium-Eaton) for relief of spasticity. Nelson JR West J Med; 1975 Aug; 123(2):131. PubMed ID: 1179721 [No Abstract] [Full Text] [Related]
47. Dantrolene sodium in the treatment of malignant hypertension. Harrison GG; Chapman DC S Afr Med J; 1982 Oct; 62(15):503-4. PubMed ID: 7123413 [No Abstract] [Full Text] [Related]
48. Dantrolene sodium approved for malignant hyperthermia. FDA Drug Bull; 1979 Nov; 9(5):27. PubMed ID: 510837 [No Abstract] [Full Text] [Related]
49. [Non-rigid type malignant hyperthermia and dantrolene sodium]. Hayakawa A; Shimonaka H; Uematsu H; Yamamoto M Masui; 1988 Oct; 37(10):1243-8. PubMed ID: 3058994 [No Abstract] [Full Text] [Related]
50. Oral dantrolene sodium for tonsillectomy pain. Wackym PA; Abdul-Rasool IH Otolaryngol Head Neck Surg; 1988 Dec; 99(6):607. PubMed ID: 3148126 [No Abstract] [Full Text] [Related]
51. Dantrolene sodium in the management of patients at risk from malignant hyperthermia. Bronstein SL; Ryan DE; Solomons CC; Mahowald MC J Oral Surg; 1979 Oct; 37(10):719-24. PubMed ID: 289734 [TBL] [Abstract][Full Text] [Related]
52. [Transient normalisation of CK blood levels in patients susceptible to malignant hyperthermia by oral administration of dantrolene (author's transl)]. Bernhardt D Anaesthesist; 1982 May; 31(5):252-4. PubMed ID: 7103034 [TBL] [Abstract][Full Text] [Related]
53. Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. Granato JE; Stern BJ; Ringel A; Karim AH; Krumholz A; Coyle J; Adler S Ann Neurol; 1983 Jul; 14(1):89-90. PubMed ID: 6614876 [TBL] [Abstract][Full Text] [Related]
54. [Experimental study of dantrolene sodium in anesthetic malignant hyperthermia in the pietrain-strain pig]. Adnet P; Krivosic-Horber R; Guevart E; Theunynck D; Vincent A Cah Anesthesiol; 1986 Oct; 34(6):463-7. PubMed ID: 3801956 [No Abstract] [Full Text] [Related]
55. Physical assessment and differential diagnosis of the poisoned patient. Olson KR; Pentel PR; Kelley MT Med Toxicol; 1987; 2(1):52-81. PubMed ID: 3547006 [TBL] [Abstract][Full Text] [Related]
56. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Ward A; Chaffman MO; Sorkin EM Drugs; 1986 Aug; 32(2):130-68. PubMed ID: 3527659 [TBL] [Abstract][Full Text] [Related]